Fluticasone/Umeclidin/Vilanter
Brand name: Trelegy Ellipta
Rank #9 of 500 drugs by total cost
$1.81B
Total Cost
2,046,216
Total Claims
$1.81B
Total Cost
36,178
Prescribers
$885
Cost per Claim
368,651
Beneficiaries
2,714,181
30-Day Fills
$50K
Avg Cost/Provider
57
Avg Claims/Provider
About Fluticasone/Umeclidin/Vilanter
Fluticasone/Umeclidin/Vilanter (sold as Trelegy Ellipta) was prescribed 2,046,216 times by 36,178 Medicare Part D providers in 2023, costing the program $1.81B. At $885 per claim, this is a high-cost medication.
💰 This drug alone accounts for 0.7% of all Medicare Part D drug spending.
Related Drugs by Cost
| # | Drug | Total Cost | Claims |
|---|---|---|---|
| 6 | Adalimumab (Humira(Cf) Pen) | $2.17B | 240,925 |
| 7 | Lenalidomide (Revlimid) | $2.15B | 130,834 |
| 8 | Insulin Glargine,hum.Rec.Anlog (Lantus Solostar) | $1.94B | 3,118,259 |
| 9 | Fluticasone/Umeclidin/Vilanter (Trelegy Ellipta) | $1.81B | 2,046,216 |
| 10 | Dapagliflozin Propanediol (Farxiga) | $1.65B | 1,666,200 |
| 11 | Sitagliptin Phosphate (Januvia) | $1.54B | 1,567,668 |
| 12 | Sacubitril/Valsartan (Entresto) | $1.30B | 1,220,812 |
Data from CMS Medicare Part D Prescriber-Drug Public Use File, 2023. Methodology